GlobeNewswire

Invivoscribe Submits Pre-Market Approval Application in Japan and Panel Track Supplement in the US to Screen Acute Myeloid Leukemia (AML) Patients for FLT3 Mutations

Share

SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Invivoscribe Technologies, Inc. announced today that they have submitted to Japan's Pharmaceutical and Medical Devices Agency (PMDA) and the US Food and Drug Administration (FDA) product registrations based on the ongoing Phase III CL-0301 ADMIRAL study evaluating gilteritinib for the treatment of FLT3 mutation-positive (FLT3mut+) relapsed or refractory acute myeloid leukemia (AML) in adult patients.

Invivoscribe Technologies Inc., in collaboration with Astellas Pharma Inc., has developed a companion diagnostic to aid in identifying these FLT3mut+ AML patients.  In Japan, Invivoscribe submitted a pre-market approval application (Shonin) with the PMDA for the LeukoStrat® CDx FLT3 Mutation Assay and in the United States, Invivoscribe submitted a Panel Track Supplement to update the FDA-approved LeukoStrat CDx FLT3 Mutation Assay's Intended Use, specific for gilteritinib, should it be approved.

The LeukoStrat CDx FLT3 Mutation Assay is a PCR-based in vitro diagnostic test designed to detect internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations D835 and I836 in the FLT3 gene in genomic DNA extracted from mononuclear cells obtained from peripheral blood or bone marrow aspirates of patients diagnosed with AML. Invivoscribe was the first company to receive FDA approval for an AML companion diagnostic, with the approval of the LeukoStrat CDx FLT3 Mutation Assay in April of 2017.  

"These submissions in Japan and the US represent a significant step in our ongoing efforts to harmonize molecular diagnostic testing for what is one of the most important driver mutations in AML in support of precision medicine," said Jeffrey Miller, CSO & CEO of Invivoscribe.

According to the American Cancer Society, each year around 20,000 new cases of AML are diagnosed in the US alone, with one-third of these being FLT3mut+.

Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and bioinformatics tools to advance the fields of personalized molecular diagnostics and personalized molecular medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies developing and commercializing companion diagnostics.

For additional information please visit www.invivoscribe.com.

CONTACT:
Kevin Dobyns 858-224-6600




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Invivoscribe, Inc. via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Standard & Poor’s has affirmed Arion Bank’s long term credit rating BBB+ but revised the outlook from stable to negative23.7.2019 20:32:00 CESTPress release

Standard & Poor’s has affirmed Arion Bank’s long term credit rating BBB+ but revised the outlook from stable to negative. The Bank’s short term credit rating remains A-2. Main comments from Standard & Poor’s: The affirmation of the bank’s ratings reflects that Arion Bank maintains a solid market position in Iceland, with relatively advanced digitalized banking platforms while its exceptional capitalization counterbalances it’s geographic and loan book concentrations. Standard & Poor’s see Arion Bank as being well ahead of many other European banks in its preparation for technological disruption In a fiercely competitive environment, no longer supported by a strong economy, Icelandic banks' business prospects and earnings have become weaker. Furthermore, the role of pension funds in lending distorts Icelandic banks' competitive environment in terms of business generation and margins. Therefore it is seen as a negative trend for industry risk. Overall, economic risks for Icelandic banks

All Regulatory Clearances for Saxo Bank and BinckBank obtained to close the Offer23.7.2019 18:20:00 CESTPress release

This is a joint press release by BinckBank N.V. (BinckBank), Star Bidco B.V. (the Offeror) and Saxo Bank A/S (Saxo Bank, pursuant to Section 4, paragraph 3 of the Dutch decree on public takeover bids (Besluit openbare biedingen Wft) in connection with the recommended public offer by the Offeror for all the issued and outstanding ordinary and priority shares in the capital of BinckBank (the Offer). This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities. Any offer will be made only by means of the Offer Memorandum dated 12 March 2019 (the Offer Memorandum). This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States or Canada or in any other jurisdiction in which such release, publication or distribution would be unlawful. Terms not defined in this press release will have the meaning as set forth in the Offer Memorandum. All Regulatory Cleara

Golar LNG Partners LP Cash Distributions23.7.2019 18:13:00 CESTPress release

Golar LNG Partners LP (“the Partnership”) (NASDAQ: GMLP) announced today that its board of directors has approved a quarterly cash distribution with respect to the quarter ended June 30, 2019 of $0.4042 per common and general partner unit. This cash distribution will be paid on August 14, 2019 to all common and general partner unitholders of record as of the close of business on August 7, 2019. A cash distribution of $0.546875 per Series A preferred unit (NASDAQ: GMLPP) for the period from May 15, 2019 through August 14, 2019 has also been declared. This will be payable on August 15, 2019 to all Series A preferred unitholders of record as at August 8, 2019. Golar LNG Partners LP Hamilton, Bermuda July 23, 2019 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act

ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS23.7.2019 18:00:00 CESTPress release

Almere, The Netherlands July 23, 2019, 6 p.m. CET ASM INTERNATIONAL N.V. REPORTS SECOND QUARTER 2019 RESULTS ASM International N.V. (Euronext Amsterdam: ASM) today reports its second quarter 2019 operating results (unaudited) in accordance with IFRS. FINANCIAL HIGHLIGHTS EUR million Q2 2018 Q1 2019 Q2 2019 New orders 175.9 235.0 373.1 Net sales 208.7 248.8 363.3 Gross profit margin % 42.1 % 41.3 % 59.0 % Operating result 38.3 47.0 150.2 Result from investments (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013) 21.6 3.1 2.0 Amortization intangible assets (resulting from the sale of ASMPT stake in 2013) (3.0 ) (3.4 ) (3.4 ) Net earnings 59.4 49.4 121.6 Normalized net earnings (excluding amortization intangible assets resulting from the sale of ASMPT stake in 2013 and result from sale of ASMPT shares) 62.4 52.8 125.0 • New orders were €373 million. Excluding €103 million related to the patent litigation settlement new orders were €270 million. • Net